Managing Patients With Treatment Resistant Depression

Lisa Harding, MD, and Angelos Halaris, MD, PhD, APA, ACNP, CINP, review patient case scenarios of treatment resistant depression and discuss management of the disease—most notably, the use of intranasal esketamine as a therapy option.

EP1: Case 1: Newly Diagnosed Treatment Resistant Depression

October 21st 2021

Lisa Harding, MD, and Angelos Halaris, MD, PhD, APA, ACNP, CINP, review a case of a 26-year-old male patient who was recently diagnosed with treatment resistant depression

EP2: Case 1: An Overview of Treatment Resistant Depression

October 21st 2021

Drs Harding and Halaris provide an overview of treatment resistant depression, including prevalence and determining a diagnosis.

EP3: Case 2: Prescribing Intranasal Esketamine

October 21st 2021

Two psychiatrists review the case of 42-year-old female patient with a treatment resistant depression diagnosis that was prescribed intranasal esketamine.

EP4: Case 2: Starting a Patient on Intranasal Esketamine

October 21st 2021

Lisa Harding, MD, and Angelos Halaris, MD, PhD, APA, ACNP, CINP, discuss their thoughts on starting treatment with intransal esketamine and what to expect.

EP5: Targeting the Glutamatergic System for Treatment Resistant Depression

October 21st 2021

Two experts examine the impact of targeting the glutamatergic system as therapy for treatment resistant depression.

EP6: Phase 3 TRANSFORM Trial

October 21st 2021

Drs Harding and Halaris evaluate the phase 3 TRANSFORM trial that studied intranasal esketamine as a therapy option for treatment resistant depression.

EP7: Intransal Esketamine and REMS

October 21st 2021

Two psychiatrists discuss the importance of intranasal esketamine having a Risk Evaluation and Mitigation Strategy (REMS) and how that impacts treatment for treatment resistant depression.

EP8: Health Care Requirements to be Aware of for Intranasal Esketamine

October 21st 2021

Drs Harding and Halaris review the requirements health care settings must follow in order to procure, prescribe, and dispense intranasal esketamine as treatment resistant depression therapy.

EP9: Advising Clinicians on Using Intranasal Esketamine

October 21st 2021

Lisa Harding, MD, and Angelos Halaris, MD, PhD, APA, ACNP, CINP, give advice to any clinicians considering the use of intranasal esketamine for treatment resistant depression.